NCT00165620已完成2 期
A Randomized, Open, Parallel, Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
- 主要终点
- Efficacy
研究概览
简要总结
To establish the optimum injection rate for E7337 (Iomeron 350) in dynamic CT in patients who have hepatic lesions.The primary endpoint for efficacy is the contrast enhancement effect in the early arterial phase, and the primary safety endpoints are warming sensation and vascular pain.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteira:
- •Patients scheduled for a dynamic CT scan of the liver who have at least one hepatic lesion that has been confirmed by diagnostic imaging (ultrasonography, etc.) between 1 and 35 days before the start of the study treatment.
- •Patients who are 20 years or older at the time of obtaining informed consent.
排除标准
- •Items that may affect the safety evaluation of E7337
- •Patients who have undergone or are scheduled to undergo an examination using another contrast agent between 7 days before administration of E7337 and the time of follow-up examinations on Day 8 after administration.
- •Patients for whom follow-ups seem to be difficult to conduct until the time of examination on Day 8 (i.e. when it may fail to evaluate delayed adverse drug reactions).
- •Patients who have undergone or are scheduled to undergo surgical treatment or a therapy such as percutaneous ethanol injection therapy, percutaneous microwave coagulation therapy, radiofrequency ablation, or transcatheter arterial embolization, etc., from the time diagnostic imaging such as abdominal ultrasonography is performed up until follow-up examinations are conducted on Day 8 after administration.
- •Patients who continuously need to take analgesics between the morning of administration of E7337 and the completion of CT examinations.
- •Patients who are currently participating in another clinical study.
- •Patients who participated in another clinical study within 3 months prior to providing informed consent for this study.
- •Patients weighing less than 55 kg (body weight at the time of obtaining informed consent).
- •General concerns relating to the safety of the subject.
- •Patients in the acute stage with clinically unstable symptoms, or in a life-threatening condition (when it is expected that emergency treatment is required between the time of registration and the end of the follow-up period, or when the patient is not expected to survive for 3 months following administration of E7337, etc.)
- •Patients with a history of hypersensitivity to iodine or iodinated contrast agents.
- •Patients with serious thyroid disease (goiter, hyperthyroidism, etc.)
- •Patients with serious cardiopathy (NYHA functional class IV heart failure as described in Appendix 5, shock, cyanosis, peripheral circulatory insufficiency, ventricular tachycardia, ventricular fibrillation, or complete atrioventricular block)
- •Patients with serious hepatopathy (symptoms of liver failure [fulminant hepatitis] such as a disturbance of consciousness corresponding to grade 3 in the Criteria for Grading Adverse Drug Reactions of Medicinal Products in Appendix 5).
- •Patients with moderate or serious nephropathy (acute or chronic renal failure, hydronephrosis, nephrotic syndrome, or uremia with serum creatinine levels of 2.0 mg/dL or above, corresponding to grade 2 or above in the Criteria for Grading Adverse Drug Reactions of Medicinal Products in Appendix 5).
- •Patients with bronchial asthma
- •Patients with acute pancreatitis
- •Patients with macroglobulinemia
- •Patients with multiple myeloma
- •Patients with tetany
- •Patients with pheochromocytoma or who are suspected to be pheochromocytoma
- •Women of pregnant, childbearing potential, or lactating
- •Patients with a history of hypersensitivity to drug(s)
- •Patients with hypertension under medication
- •Patients with diabetes under medication
- •Patients with serious illness myasthenia
- •Patients judged to be ineligible for study entry by an investigator or subinvestigator for any other reasons
结局指标
主要结局
Efficacy
Contrast enhancement effect in the early arterial phase
Safety
Warming sensation and vascular pain
次要结局
- Safety and arterial, portal venous and liver parenchymal CT values (HU)
- Symptoms and signs（excluding warming sensation and vascular pain ）, and life signs (blood pressure, pulse), etc., and laboratory tests (hematology, serum chemistry) conducted before and after administration of the investigational agent
- Efficacy
- Contrast enhancement effect in the portal phase
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
CT DOSE CollaboratoryIonizing Radiation ExposureQuality ImprovementNCT03000751University of California, San Francisco864,080
已完成
不适用
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary CancerAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerMetastatic Extrahepatic Bile Duct CancerRecurrent Adult Primary Liver CancerRecurrent Extrahepatic Bile Duct CancerStage D Adult Primary Liver Cancer (BCLC)Unspecified Adult Solid Tumor, Protocol SpecificNCT02088775Fox Chase Cancer Center44
已完成
不适用
Personalization of CM Injection Protocols in Coronary Computed Tomographic AngiographyCoronary Artery CalcificationCardiac DiseaseNCT03292354Maastricht University Medical Center327
已完成
2 期
Cone Beam CT for Daily Image Guidance - Prostate CancerProstatic NeoplasmsNCT00188786University Health Network, Toronto30
已完成
不适用
A new dose-finding trial design to identify the optimal therapeutic dose of an upper limb intervention for people after strokeStrokeISRCTN23054430niversity of East Anglia (UK)24